Apollomics, Inc.
APLMHealthcare|Biotechnology|US
$19.00
+2.02 (+11.90%)
Cash / Share
$7.78
Financials
Financial Snapshot
Market Cap
$55.4M
Enterprise Value
$52.8M
Revenue (TTM)
$8.7M
Net Income (TTM)
-$64.8M
Cash & Investments
$3.3M
Net Cash
$2.6M
Free Cash Flow (TTM)
-$46.8M
Operating CF (TTM)
-$46.7M
Debt/Equity
-0.20
Cash Runway & Burn Rate
Cash on Hand
$3.3M
Quarterly Burn
$11.7M
Monthly Burn
$3.9M
Est. Runway
~0.3 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $74.1M | $154.4M | $94.5M | $54.6M | $37.8M | $9.8M | $3.3M | $3.3M | |
| Operating Cash Flow | -$21.9M | -$35.7M | -$43.3M | -$42.8M | -$43.2M | -$28.7M | -$10.4M | -$46.7M | |
| Free Cash Flow | -$22.8M | -$35.8M | -$50.9M | -$43.2M | -$43.2M | -$28.8M | -$10.4M | -$46.8M | |
| Capital Expenditure | -$857.0K | -$144.0K | -$7.5M | -$367.0K | -$6.0K | -$24.0K | $0.00 | -$24.0K | |
| Financing Cash Flow | $9.5M | $125.5M | -$1.6M | -$294.0K | $21.2M | $468.0K | $3.7M | $4.1M |
R&D Spending
R&D (TTM)
$30.1M
R&D Intensity
346.0%
R&D Growth vs Prior
+444.2%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.8M | $2.0K | $323.0K | $821.0K | $198.0K | $8.5M | $8.7M | |
| R&D Expense | $18.4M | $31.4M | $35.6M | $35.5M | $34.2M | $24.6M | $5.5M | $30.1M | |
| R&D % of Revenue | — | 1710.6% | 1778400.0% | 10977.4% | 4164.8% | 12407.1% | 65.1% | 346.0% | |
| SG&A | $5.9M | $11.0M | $15.3M | $9.9M | $20.6M | $17.8M | $12.4M | $30.2M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $1.8M | $2.0K | $323.0K | $821.0K | $198.0K | $8.5M | $8.7M | |
| Cost of Revenue | $369.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $255.0K | $0.00 | |
| Gross Profit | -$369.0K | $1.8M | $2.0K | $323.0K | $821.0K | $198.0K | $8.2M | $8.7M | |
| R&D | $18.4M | $31.4M | $35.6M | $35.5M | $34.2M | $24.6M | $5.5M | $30.1M | |
| SG&A | $5.9M | $11.0M | $15.3M | $9.9M | $20.6M | $17.8M | $12.4M | $30.2M | |
| Operating Income | -$24.7M | -$40.6M | -$50.9M | -$45.1M | -$54.0M | -$42.1M | -$9.5M | -$51.6M | |
| Interest Expense | $46.0K | $72.0K | $83.0K | $93.0K | $150.0K | $179.0K | $65.0K | $65.0K | |
| Pretax Income | -$45.8M | -$74.9M | -$94.8M | -$240.8M | -$172.6M | -$53.6M | -$10.9M | -$64.5M | |
| Net Income | -$45.9M | -$74.8M | -$94.8M | -$240.8M | -$172.6M | -$53.9M | -$10.9M | -$64.8M | |
| EPS (Diluted) | -0.53 | -20.70 | -23.45 | -61.60 | -231.99 | -52.80 | -7.57 | -62.49 | |
| EBITDA | -$45.3M | -$40.0M | -$49.6M | -$43.3M | -$52.9M | -$40.8M | -$9.2M | -$50.1M | |
| Shares Out. (M) | 0.87 | 0.87 | 0.87 | 0.87 | 0.74 | 0.93 | 1.44 | 0.42 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.5M | $130.6M | $46.7M | $32.7M | $32.1M | $9.8M | $3.3M | $3.3M | |
| Short-Term Investments | $35.6M | $23.7M | $47.7M | $21.9M | $5.8M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $75.4M | $156.7M | $99.4M | $55.8M | $39.9M | $10.3M | $6.1M | $6.1M | |
| Total Assets | $79.1M | $169.9M | $123.4M | $76.5M | $55.4M | $13.1M | $6.7M | $6.7M | |
| Total Current Liabilities | $4.6M | $12.1M | $13.6M | $12.4M | $13.6M | $7.4M | $6.3M | $6.3M | |
| Long-Term Debt | $134.0M | $284.8M | $322.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $139.8M | $297.9M | $336.3M | $524.6M | $14.2M | $8.2M | $9.9M | $9.9M | |
| Stockholders' Equity | -$60.7M | -$127.9M | -$212.9M | -$448.1M | $41.2M | $4.9M | -$3.2M | -$3.2M | |
| Retained Earnings | -$66.7M | -$141.5M | -$235.4M | -$474.6M | -$647.0M | -$700.8M | -$711.8M | -$711.8M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.9M | -$35.7M | -$43.3M | -$42.8M | -$43.2M | -$28.7M | -$10.4M | -$46.7M | |
| Capital Expenditure | -$857.0K | -$144.0K | -$7.5M | -$367.0K | -$6.0K | -$24.0K | $0.00 | -$24.0K | |
| Free Cash Flow | -$22.8M | -$35.8M | -$50.9M | -$43.2M | -$43.2M | -$28.8M | -$10.4M | -$46.8M | |
| Investing Cash Flow | -$29.9M | $2.3M | -$39.0M | $29.1M | $21.4M | $6.0M | $218.0K | $6.2M | |
| Financing Cash Flow | $9.5M | $125.5M | -$1.6M | -$294.0K | $21.2M | $468.0K | $3.7M | $4.1M | |
| Issuance of Stock | $9.8M | $126.1M | $141.0K | $392.0K | $85.0K | $0.00 | $7.0K | $7.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$472.0K | -$528.0K | -$593.0K | $24.0M | $661.0K | $3.7M | -$172.0K | |
| Stock Based Comp. | $0.00 | $4.5M | $8.1M | $3.6M | $12.7M | $10.9M | -$979.0K | $13.2M | |
| Net Change in Cash | -$42.3M | $92.2M | -$83.9M | -$14.1M | -$619.0K | -$22.3M | -$6.5M | -$4.4M |
Dilution Tracker
Shares outstanding grew 66.5% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+66.5%
Stock Issuance (TTM)
$7.0K
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.87 | 0.87 | 0.87 | 0.87 | 0.74 | 0.93 | 1.44 | 0.42 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | -14.3% | 24.5% | 56.0% | -70.9% | |
| Stock Issuance | $9.8M | $126.1M | $141.0K | $392.0K | $85.0K | $0.00 | $7.0K | $7.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $4.5M | $8.1M | $3.6M | $12.7M | $10.9M | -$979.0K | $13.2M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% | 100.0% | |
| Operating Margin % | — | -2211.4% | -2542850.0% | -13957.0% | -6578.9% | -21280.8% | -111.4% | -593.3% | |
| Net Margin % | — | -4070.7% | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% | -745.0% | |
| EBITDA Margin % | — | -2178.3% | -2479450.0% | -13402.5% | -6440.9% | -20588.9% | -108.4% | -576.3% | |
| FCF Margin % | — | -1949.1% | -2543100.0% | -13371.8% | -5263.7% | -14528.8% | -122.0% | -537.6% | |
| ROE % | 75.6% | 58.5% | 44.5% | 53.7% | -418.6% | -1107.3% | 343.1% | 288.4% | |
| ROA % | -58.1% | -44.0% | -76.8% | -314.9% | -311.6% | -411.2% | -162.9% | -162.9% | |
| ROIC % | -32.9% | -25.1% | -45.2% | -69.6% | -116.8% | -710.3% | -1586.8% | -1586.8% | |
| R&D / Revenue % | — | 1710.6% | 1778400.0% | 10977.4% | 4164.8% | 12407.1% | 65.1% | 346.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | -99.9% | 16050.0% | 154.2% | -75.9% | 4192.9% | |
| Gross Profit | 0.0% | 598.1% | -99.9% | 16050.0% | 154.2% | -75.9% | 4064.1% | |
| Operating Income | 0.0% | -64.2% | -25.1% | 11.4% | -19.8% | 22.0% | 77.5% | |
| Net Income | 0.0% | -63.0% | -26.7% | -154.0% | 28.3% | 68.8% | 79.7% | |
| EPS (Diluted) | 0.0% | -3805.7% | -13.3% | -162.7% | -276.6% | 77.2% | 85.7% | |
| Operating Cash Flow | 0.0% | -62.6% | -21.4% | 1.1% | -0.9% | 33.5% | 63.9% | |
| Free Cash Flow | 0.0% | -57.1% | -42.0% | 15.1% | -0.1% | 33.4% | 64.0% | |
| R&D Expense | 0.0% | 70.5% | 13.1% | -0.3% | -3.6% | -28.2% | -77.5% | |
| SG&A Expense | 0.0% | 86.0% | 38.5% | -34.9% | 107.5% | -13.9% | -30.0% | |
| Total Assets | 0.0% | 115.0% | -27.4% | -38.0% | -27.6% | -76.4% | -48.7% | |
| Book Value / Share | 0.0% | -110.7% | -66.4% | -110.5% | 110.7% | -90.5% | -142.0% | |
| Debt | 0.0% | 113.0% | 12.4% | -99.7% | 370.3% | -79.3% | -33.4% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | -14.3% | 24.5% | 56.0% |
Valuation
P/E (TTM)At Loss
P/S6.52
10Y Low / Med / High3.18 / 467.51 / 430941.15
P/B-2.51
EV/EBITDAAt Loss
EV/Revenue6.21
10Y Low / Med / High1.18 / 553.96 / 570274.15
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$7.78
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1867.92 | -47.83 | -42.35 | -16.82 | -0.42 | -0.18 | -2.47 | -2.51 | |
| P/S Ratio | 0.00 | 467.51 | 430941.15 | 2783.91 | 87.45 | 45.62 | 3.18 | 6.52 | |
| P/B Ratio | -14.15 | -6.72 | -4.05 | -2.01 | 1.74 | 1.86 | -8.48 | -2.51 | |
| EV/EBITDA | -21.10 | -25.43 | -23.00 | -20.04 | -0.84 | -0.01 | -2.65 | -5.64 | |
| EV/Revenue | 0.00 | 553.96 | 570274.15 | 2685.82 | 54.08 | 1.18 | 2.87 | 6.21 |
Analyst Estimates & Quality
Altman Z-Score
-148.50
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $13.3M | $20.7M | $12.8M |
| Net Income | -$176.3M | -$199.4M | -$199.4M |
| EPS | $-122.00 | $-138.00 | $-138.00 |
| # Analysts (EPS) | 1 | 1 | 1 |